Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, et al. J Allergy Clin Immunol 2022 Oct 1. pii: S0091-6749(22)01327.

Read + Share

Amedeo Smart

Independent Medical Education

Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. J Allergy Clin Immunol 2022 Oct 1. pii: S0091-6749(22)01327.
PMID: 36195170